| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Laboratory Medicine and
Pathology,*
Mayo Clinic and Mayo Foundation, Rochester,
Minnesota, and the Department of Pathology,
St. Michael's Hospital, University of Toronto, Toronto,
Ontario, Canada
Analyses of apoptosis and of the apoptosis regulatory proteins Bcl-2, Bax, Bcl-X, and Bad were done in 95 nontumorous and neoplastic pituitary tissues by terminal deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL), immunohistochemistry, and Western blotting. The apoptotic index was relatively low in all groups but was at least fourfold higher in pituitary carcinomas compared with any other groups. Pituitaries from pregnant and postpartum women had a fivefold higher apoptotic index compared with matched controls from nonpregnant females. Preoperative treatment of adenomas with octreotide or dopamine agonists did not change the apoptotic index significantly. The lowest levels of Bcl-2, Bax, and Bcl-X expression were in pituitary carcinomas as detected by immunostaining. An immortalized human pituitary adenoma cell line, HP75, developed in our laboratory using a replication-defective recombinant human adenovirus with an early large T-antigen, had a much higher level of apoptosis than nontumorous and neoplastic pituitaries. Treatment with transforming growth factor (TGF)-ß1 and protein kinase C (PKC) inhibitors increased apoptosis in this cell line. Analysis of the Bcl-2 family of proteins after treatment with TGF-ß1 and PKC inhibitors showed a 20% to 30% decrease in Bcl-X in the treated groups compared with controls. These results, which represent the first study of apoptosis in pituitaries from pregnant and postpartum cases and in pituitary carcinomas, indicate that 1) the apoptotic rate is low in nontumorous and neoplastic pituitary tissues but is relatively higher in pituitary carcinomas, 2) there are alterations in the expression of the Bcl-2 family of proteins in pituitary neoplasms with a decrease in Bcl-2 expression in pituitary carcinomas that may contribute to pituitary tumor pathogenesis and/or proliferation, and 3) cultured pituitary tumor cells respond to TGF-ß1 and PKC inhibitors by undergoing apoptotic cell death.
This article has been cited by other articles:
 |
|
 |
|
  G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Riss, L. Jin, X. Qian, J. Bayliss, B. W. Scheithauer, W. F. Young Jr., S. Vidal, K. Kovacs, A. Raz, and R. V. Lloyd Differential Expression of Galectin-3 in Pituitary Tumors Cancer Res., May 1, 2003; 63(9): 2251 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Thiruchelvam, P. Nyirady, D. M. Peebles, C. H. Fry, P. M. Cuckow, and A. S. Woolf Urinary Outflow Obstruction Increases Apoptosis and Deregulates Bcl-2 and Bax Expression in the Fetal Ovine Bladder Am. J. Pathol., April 1, 2003; 162(4): 1271 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Losa, E. Ciccarelli, P. Mortini, R. Barzaghi, D. Gaia, G. Faccani, M. Papotti, F. Mangili, M. R. Terreni, F. Camanni, et al. Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5194 - 5200. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
